JP2019503171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503171A5 JP2019503171A5 JP2018532655A JP2018532655A JP2019503171A5 JP 2019503171 A5 JP2019503171 A5 JP 2019503171A5 JP 2018532655 A JP2018532655 A JP 2018532655A JP 2018532655 A JP2018532655 A JP 2018532655A JP 2019503171 A5 JP2019503171 A5 JP 2019503171A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- nagal
- human
- polypeptide
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202729 | 2015-12-24 | ||
| EP15202729.8 | 2015-12-24 | ||
| PCT/EP2016/082304 WO2017109034A1 (en) | 2015-12-24 | 2016-12-22 | Human alpha-n-acetylgalactosaminidase polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019503171A JP2019503171A (ja) | 2019-02-07 |
| JP2019503171A5 true JP2019503171A5 (cg-RX-API-DMAC7.html) | 2020-02-06 |
| JP6956417B2 JP6956417B2 (ja) | 2021-11-02 |
Family
ID=55129455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532655A Expired - Fee Related JP6956417B2 (ja) | 2015-12-24 | 2016-12-22 | ヒトα−Ｎ−アセチルガラクトサミニダーゼポリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11040114B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3393501B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6956417B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180088919A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3008975A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017109034A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3393501B1 (en) * | 2015-12-24 | 2023-06-07 | Oxyrane UK Limited | Human alpha-n-acetylgalactosaminidase polypeptide |
| WO2019051297A1 (en) * | 2017-09-08 | 2019-03-14 | The Nemours Foundation | AGENT, DEVICE AND BLOOD CIRCULATION SYSTEM FOR TREATING LYSOSOMAL DISEASES, AND METHODS OF TREATING LYSOSOMAL DISEASES |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| EP4142802A4 (en) * | 2020-04-28 | 2024-07-24 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ANGELMAN SYNDROME |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| AU2887897A (en) | 1996-05-21 | 1997-12-09 | Novo Nordisk A/S | Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast |
| US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
| WO2006129080A1 (en) | 2005-05-31 | 2006-12-07 | The Institute Of Cancer Research: Royal Cancer Hospital | Materials and methods for transducing cells with a viral vector |
| AU2006316122A1 (en) | 2005-11-18 | 2007-05-24 | Altif Laboratories Inc. | Novel highly functional enzyme having modified substrate-specificity |
| KR20170091174A (ko) | 2007-04-03 | 2017-08-08 | 옥시레인 유케이 리미티드 | 분자의 글리코실화 |
| WO2008143354A1 (ja) | 2007-05-18 | 2008-11-27 | Tokyo Metropolitan Organization For Medical Research | 酵素補充療法用医薬組成物 |
| ES2783024T3 (es) | 2009-09-29 | 2020-09-16 | Univ Gent | Hidrólisis de la unión de manosa-1-fosfo-6-manosa a fosfo-6-manosa |
| CN103328646B (zh) | 2010-09-29 | 2021-06-18 | 奥克西雷恩英国有限公司 | 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法 |
| KR20190114003A (ko) | 2012-03-15 | 2019-10-08 | 옥시레인 유케이 리미티드 | 폼페병의 치료를 위한 방법 및 물질 |
| KR102702200B1 (ko) | 2014-12-22 | 2024-09-02 | 코덱시스, 인코포레이티드 | 인간 알파-갈락토시다제 변이체 |
| EP3393501B1 (en) * | 2015-12-24 | 2023-06-07 | Oxyrane UK Limited | Human alpha-n-acetylgalactosaminidase polypeptide |
-
2016
- 2016-12-22 EP EP16831567.9A patent/EP3393501B1/en active Active
- 2016-12-22 KR KR1020187021246A patent/KR20180088919A/ko not_active Abandoned
- 2016-12-22 US US16/063,408 patent/US11040114B2/en not_active Expired - Fee Related
- 2016-12-22 WO PCT/EP2016/082304 patent/WO2017109034A1/en not_active Ceased
- 2016-12-22 JP JP2018532655A patent/JP6956417B2/ja not_active Expired - Fee Related
- 2016-12-22 CA CA3008975A patent/CA3008975A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6396415B2 (ja) | コレステロールレベルを変更する組成物および方法 | |
| JP2019503171A5 (cg-RX-API-DMAC7.html) | ||
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| JP2019033757A (ja) | 核タンパク質の産生のための修飾ポリヌクレオチド | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| NZ602351A (en) | Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use | |
| CN113811317B (zh) | 突变vsv胞外域多肽及其用途 | |
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| JP2018510623A (ja) | Ｎｋｇ２ｄ及び腫瘍関連抗原に対する二価抗体 | |
| WO2011036443A3 (en) | Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| JP2013542913A5 (cg-RX-API-DMAC7.html) | ||
| IL288541B (en) | Vaccine against rsv | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| UA110599C2 (uk) | Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку | |
| WO2009100934A9 (en) | Identification of a novel cysteine-rich cell penetrating peptide | |
| JP2014506450A5 (cg-RX-API-DMAC7.html) | ||
| US20230075095A1 (en) | Polypeptides and their use | |
| EP4083058A2 (en) | Delivery constructs for transcytosis and related methods | |
| MX376466B (es) | Vectores de expresion para una secrecion de proteina mejorada. | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| MY146926A (en) | Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| WO2013052814A3 (en) | E1 enzyme mutants and uses thereof | |
| US20250154490A1 (en) | Mutant cytidine deaminases with improved editing precision | |
| ZA202304029B (en) | Cxcl9 and variants thereof for immunotherapy of cancer diseases |